Safety Study of APD-791 With Aspirin and/or Clopidogrel (TG1C)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02034292 |
Recruitment Status :
Terminated
(Sponsor Decision)
First Posted : January 13, 2014
Last Update Posted : February 15, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Coronary Syndrome | Drug: Clopidogrel Drug: Aspirin Drug: APD791 Drug: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Screening |
Official Title: | Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin |
Actual Study Start Date : | February 2014 |
Actual Primary Completion Date : | March 2014 |
Actual Study Completion Date : | March 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: 10mg MD
APD791 10mg Multiple dose and
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Experimental: 20mg MD
APD791 20mg Multiple dose
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Experimental: 40mg MD
APD791 40mg Multiple dose
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Experimental: 60mg MD
APD791 60mg Multiple dose
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Placebo Comparator: Placebo MD
Placebo for Multiple dose group
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Experimental: 120mg SD
APD791 120mg Single dose
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Experimental: 240mg SD
APD791 240mg Single dose
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Experimental: 320mg SD
APD791 320mg Single dose
|
Drug: Clopidogrel Drug: Aspirin Drug: APD791 |
Placebo Comparator: Placebo SD
Placebo for Single dose
|
Drug: Clopidogrel Drug: Aspirin Drug: Placebo |
- To assess the safety of APD791 when orally co-administered with Aspirin and Clopidogrel in healthy subjects [ Time Frame: safety review will be conducted at every end of dosing (about every 2 or 3 weeks) ]Adverse reaction monitoring for subjective or objective symptoms Physical examination Vital signs 12-electrode ECG Laboratory tests
- Pharmacokinetic characteristic evaluation variable [ Time Frame: After last patient last visit. About 8month later since start of the study. ]
Non-compartmental analysis is conducted by using APD791 and its metabolite, M1 and M2 and the following pharmacokinetic evaluation variables are calculated.
Cmax0-12, Cmax,ss (Day 7 only), Cmin,ss (Day 7 only), tmax0-12, tmax,ss (Day 7 only), λz, t1/2β, AUC0-12 (Day 1 only), AUCinf, Accumulation index, CL/F, MRT, Vz/F
- Pharmacodynamic characteristic evaluation variable [ Time Frame: Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group. ]Pharmacodynam1) % inhibition of serotonin-stimulated platelet aggregation 2) Change in % inhibition of serotonin-stimulated platelet aggregation 3) % inhibition of TRAP-induced platelet aggregation ic characteristic evaluation variable

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- a healthy adult between 20 and 45 years old at the time of visit for screening
- a person who is able to give written consent
- a person between 50 and 85 kg at the time of visit for screening
- a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing
- a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal
- a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm
- a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL)
- a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator
- a person who voluntarily decides to participate in this clinical trial and gives written consent on strict clinical trial compliance
- a person whose blood can be collected during a study period with visit for monitoring
Exclusion Criteria:
- a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening
- a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug
- a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening
- a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening
- a person with the medical history of epilepsy or convulsion
- a person with the medical history of internal organ transplant
- a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period
- a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision
- a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction
- a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening
- a person with the medical history of alcohol abuse within two years from the time of visit for screening
- a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening
- a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening
- a person taking other clinical trial drugs within 90 days from the time of visit for screening
- a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening
- a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)
- a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)
- a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening
- a person decided to be inappropriate to participate in this clinical trial according to investigator's medical decision on the result of laboratory tests, such as complete blood cell count, general chemical test, clinicochemical urinalysis, and physical examination, vital signs, ECG, other tests excluding exclusion criteria 17 items conducted before subject selection for a clinical trial
Responsible Party: | IlDong Pharmaceutical Co Ltd |
ClinicalTrials.gov Identifier: | NCT02034292 History of Changes |
Other Study ID Numbers: |
ID-TG1C-1301 |
First Posted: | January 13, 2014 Key Record Dates |
Last Update Posted: | February 15, 2019 |
Last Verified: | February 2019 |
Acute Coronary Syndrome Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Aspirin Clopidogrel APD791 Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents |
Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Serotonin 5-HT2 Receptor Antagonists Serotonin Antagonists |